Sign Out
Hypersensitivity to the active substance or to any of the excipients listed in Description.
REKAMBYS must not be co-administered with the following medicinal products, as significant decreases in rilpivirine plasma concentrations may occur (due to CYP3A enzyme induction), which may result in loss of therapeutic effect of REKAMBYS (see Interactions): the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin; the antimycobacterials rifabutin, rifampicin, rifapentine; the systemic glucocorticoid dexamethasone, except as a single dose treatment; St John's wort (Hypericum perforatum).
